Healthcare Highlights: Baxter International Inc. (NYSE:BAX) Hemophilia B Results Came Constructive, Amgen Inc. (NASDAQ:AMGN) Purchasing deCODE Genetics

  on Dec 11,2012 Posted in Business News ,Featured
 
Share |
We're on   

Amgen Inc. (NASDAQ:AMGN) decided to purchase Iceland-located deCODE genetics Inc. , which finds genetic risk factors for dozens of diseases, for almost $415 million.

Amgen, Inc. (NASDAQ:AMGN) moved up +1.61% with the closing price of $89.74. The overall volume in the last trading session was 4.49 million shares. Its fifty two week range was $57.14-$89.95. The total market capitalization remained $68.86 billion.

AMGN is ahead of its 52 week low with 63.33% and its last month’s price volatility remained 1.46%. Its beta coefficient was 0.41 with a target price of $93.87. AMGN has institutional ownership remained 81.23%. Company’s current year earnings per share grew with -15.78% while the five years EPS growth rate was +10.25%.

Zogenix Inc. (NASDAQ:ZGNX) stock declined following news on Friday that a US Food and Drug Administration board voted against accepting the firm’s planned pain drug. On Monday, Oppenheimer experts lowered the stock rating to perform from outperform.

In last trading session, Zogenix, Inc. (NASDAQ:ZGNX) reported the loss of -50.85% to close at $1.16 and its overall traded volume was 15.32 million shares, more than the average volume of 868,376.00.

ZGNX has earnings per share of -$1.00 with the net profit margin of -164.86% and operating margin of -125.99%.

Baxter International Inc. (NYSE:BAX) stated that results from a study assessing its newcure for patients with hemophilia B were optimistic.

The medical product firm’s BAX 326–its untried recombinant factor IX protein for the cure and prophylaxis of bleeding episodes for patients with hemophilia B above 12 years of age, was lately given orphan-drug label by the US Food and Drug Administration.

Baxter International Inc. (NYSE:BAX) surged +0.65% and closed at $65.49 in last trading session. The overall traded volume was 2.81 million shares. Stock’s 52 weeks high price was $68.91 and 52 weeks low price was $47.55.

In its share capital BAX has 549.38 million outstanding shares while 546.40 million shares have been floated in market. Company’s current year earnings per share grew with 62.36% while the five years EPS growth rate was +12.74%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a 25.54% gain to $6.93 in the latest trading session has changed its distance from 200-Day Moving Average to +37.85% and 50-Day Moving Average to +18.74%. It captures $429.52 million in market value. The mean rating 1.30 is set by analysts. The company is projected to report -$0.25per share for the quarter ending Dec-12 as compared to -$0.30 earned a year earlier, according to 6 analysts surveyed by Reuters. The average EPS forecast of 6 analysts for the full-year is -$1.00, up as compared to -$1.18 earned a year ago.

Johnson & Johnson (NYSE:JNJ)’s shares touched a high of $70.80 before closing at $70.60, an increase of $0.15. The trading volume was 9.70 million shares. Since hitting a 52-week low of $61.71 on Jun 01, 2012, the stock has managed to stay 16.46% higher from that level. The latest gain caused shares to increase their 2012 gain to 11.64%.

 



 

Leave a Reply